FDA has granted pediatric exclusivity for Eylea. This grant extends the period of U.S. market exclusivity for Eylea by an additional six months through May 17, 2024.- Regeneron
Regeneron Pharmaceuticals, Inc. announced the FDA has granted pediatric exclusivity for Eylea (aflibercept) Injection. This grant extends the period of U.S. market exclusivity for Eyleaby an additional six months through May 17, 2024.
The pediatric exclusivity determination is based on data from two Phase III trials – BUTTERFLEYE and FIREFLEYE – which were submitted in response to the FDA's Written Request to evaluate the use of Eylea as a treatment for retinopathy of prematurity (ROP) in preterm infants. The two Phase III trials also formed the basis of a supplemental Biologics License Application for Eylea in ROP that was recently accepted for Priority Review by the FDA. The lead sponsors of the trials were Regeneron for BUTTERFLEYE and Bayer for FIREFLEYE.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.